Enriqueta Felip Font
Enriqueta Felip Font
FACULTATIU ESPECIALISTA ONCOLOGIA MÈDICA
Veure més especialistes a
Barcelonabarcelona
Dades destacades
- ESMO Women for Oncology2015
- Última publicació:Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial.
Dades del professional
Hospital Quirónsalud Barcelona
FACULTATIU ESPECIALISTA ONCOLOGIA MÈDICA
Juliol 2023
Estudi
Diplomada en medicina
Universidad Autónoma de Barcelona
Doctorat
Universidad Autónoma de Barcelona
Professora Associada
Universidad Autónoma de Barcelona
Desenvolupament de fàrmacs per a teràpia de precisió en càncer de pulmó en estadi IV
Assaig NATCH
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial.
Journal Article
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
Journal Article
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-ß and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
Journal Article, Research Support, Non-U.S. Govt
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-ß and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
Journal Article
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival.
Journal Article
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Govt
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Govt
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
Clinical Trial, Phase II, Journal Article
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
Journal Article
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
Journal Article, Comment
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Journal Article, Research Support, Non-U.S. Govt
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Govt
ESMO Women for Oncology
ESMO
Demana cita amb aquest professional
Articles de
Consulta els darrers articles a Tu canal de salud.
Vídeos de
Consulta el contenido multimedia de este profesional.
Àrea personal de salut: Mi Quirónsalud
Accedeix a qualsevol hora del dia per tenir cura de la teva salut i la dels teus.
Mi Quirónsalud és el teu espai personal privat i segur, on pots sol·licitar i gestionar les teves cites o consultar els teus informes clínics sense esperes ni desplaçaments.
Descobreix-ho!